Navigation Links
Sangamo BioSciences Reports Third Quarter 2013 Financial Results
Date:10/23/2013

porting Ceregene's Investigational New Drug (IND) applications. In addition, Sangamo acquired Ceregene's preclinical and clinical therapeutic programs including its ongoing double-blind, placebo-controlled Phase 2 trial to evaluate its NGF-AAV (CERE-110) in Alzheimer's disease and the proprietary needle device for brain delivery of AAV. The Company does not expect the acquisition, including the ongoing Phase 2 clinical trial, to have any impact on its financial guidance regarding 2013 operating expenses or yearend cash. 
  • Notice of Allowance for New Patent Application Covering Genome Modification Technology.  On August 14, Sangamo announced that the United States Patent and Trademark Office (USPTO) had issued a Notice of Allowance for the U.S. patent application (US 20110301073) entitled "Novel DNA-binding Proteins and Uses Thereof."  The claims cover core architectural aspects of engineered Transcription Activator-Like Effectors, or TALEs, which enable these proteins to be useful in potential therapeutic applications of genome editing or gene regulation and for the efficient use of the technology in biomedical research and plant applications. 
  • Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome. On July 17, Sangamo announced the publication of groundbreaking research using zinc finger DNA-binding protein (ZFP) technology to insert a gene that permanently "silences" the extra copy of chromosome 21, which is the root cause of Down syndrome (DS). This advance, accomplished in induced pluripotent stem cells (iPSCs) derived from DS patients, provides a model to study the basic biology of DS which may enable the development of drugs that can potentially rebalance the cellular processes and pathologies that are impacted by this disorder. 
  • Financial Guidance

  • Cash and Investments: Subsequent to its recent public offering of common stock, Sangamo expects that its c
    '/>"/>

  • SOURCE Sangamo BioSciences, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
    2. Sangamo BioSciences Proposes Public Offering Of Common Stock
    3. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
    4. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
    5. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
    6. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
    7. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
    8. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
    9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
    10. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
    11. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2014)... Utah (PRWEB) August 27, 2014 Varian ... will expand its current Salt Lake City manufacturing facility ... outside of Utah to ultimately create 1,000 new full ... years. , “Utah is home to hardworking people ... can be credited with Varian’s success in the manufacturing ...
    (Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... materials that are readily decomposed by the ... conventional non-degradable packaging in terms of raw ...
    (Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316662/Global-Chelating-Agents-Market-2014-2018.html About Chelating Agent ... can form covalent bonds with metal ions, thereby ... effect that some metal-ions have on chemical processes, ...
    (Date:8/27/2014)... (PRWEB) August 27, 2014 “We are ... technology vendors,” said Ven Thangaraj, CEO of Radiant Sage. ... that are taking the imaging corelab market to a ... corelabs and research organizations to efficiently and effectively manage ... the data to be analyzed and read by trained ...
    Breaking Biology Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2
    ... 13 Jennerex, Inc. (San Francisco, CA,and Ottawa, ... that Samantha Miller has been appointed to the ... Ms. Miller has over 15 ... has negotiated, executed and managed numerous,global partnerships, as ...
    ... pleased to announce the appointment of Barry Lee as ... his 24 years of pharmaceutical sales and,marketing experience to ... the company. , (Photo: ... "We are extremely pleased to welcome Mr. Lee to ...
    ... risk to,patient safety in an economic downturn, the National ... Safety Congress will directly address,this issue through an extensive ... new thinking and tools critical to keeping patients,safe. , ... , This highly acclaimed annual ...
    Cached Biology Technology:Jennerex Appoints Samantha Miller as Vice President of Corporate Development 2Patient Safety in Challenging Economic Times is Focus of NPSF Annual Congress on May 20-22 2
    (Date:8/28/2014)... German . ... the help of sophisticated assembly lines. Mobile assembly carriers, on ... of these assembly lines. In the case of a car ... arranged in a precise spatial and chronological sequence, resulting in ... The creation of such an assembly line at molecular level ...
    (Date:8/28/2014)... (LMU) in Munich have assigned a number of ... arthropods. These animals lived in shallow marine habitats ... found in Jurassic strata. , Before they ... habitat and were fossilized some 435 million years ... the Silurian seas although they were not ...
    (Date:8/27/2014)... mysteries of the human genome was unveiled today in ... detailed comparison yet of how the genomes of the ... research, appearing August 28 in in the journal ... three species, genomes is "read out," and how their ... results add billions of entries to a publicly available ...
    Breaking Biology News(10 mins):Nanoscale assembly line 2Nanoscale assembly line 3Paleontology: Oldest representative of a weird arthropod group 2Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4
    ... of harmful mercury in plants and animals, a new study ... Aquarium has compared levels of the chemical in captive dolphins ... fed a controlled diet, while the wild mammals dined on ... The study found lower levels of mercury in the captive ...
    ... medical information, but the sight of a needle often causes ... a team of researchers in Israel, however, can reveal much ... simply by shining a light through the skin. This optical ... high-resolution images of blood coursing through our veins without the ...
    ... University of Singapore,s (NUS) Department of Biological Sciences and Mechanobiology ... that is undergoing preclinical trials as a potential drug ... growing into a tumour. This drug-led compound is named BPTES. ... has provided evidence showing how a drug-lead compound suppresses tumour ...
    Cached Biology News:Mercury in dolphins: Study compares toxin levels in captive and wild sea mammals 2Mercury in dolphins: Study compares toxin levels in captive and wild sea mammals 3New microscope uses rainbow of light to image the flow of individual blood cells 2New microscope uses rainbow of light to image the flow of individual blood cells 3Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2